Boston Scientific Corporation  

(Public, NYSE:BSX)   Watch this stock  
Find more results for bsx
24.28
-0.06 (-0.25%)
After Hours: 24.29 +0.01 (0.04%)
Jul 29, 5:36PM EDT  
NYSE real-time data - Disclaimer
Currency in USD
Range 23.98 - 24.56
52 week 14.18 - 24.79
Open 24.33
Vol / Avg. 13.05M/11.80M
Mkt cap 33.89B
P/E     -
Div/yield     -
EPS -0.03
Shares 1.36B
Beta 0.98
Inst. own 95%
Oct 26, 2016
Q3 2016 Boston Scientific Corp Earnings Release (Estimated) - 9:30AM EDT - Add to calendar
Jul 28, 2016
Q2 2016 Boston Scientific Corp Earnings Release
Jul 28, 2016
Q2 2016 Boston Scientific Corp Earnings Call - Webcast
Jun 9, 2016
Boston Scientific Corp at Goldman Sachs Global Healthcare Conference
Jun 7, 2016
Boston Scientific Corp at Jefferies Healthcare Conference - Webcast
May 12, 2016
Boston Scientific Corp at Bank of America Merrill Lynch Health Care Conference
May 5, 2016
Boston Scientific Corp Investor Update
May 5, 2016
Boston Scientific Corp at Deutsche Bank Health Care Conference - Webcast
May 4, 2016
Boston Scientific Corp Annual Shareholders Meeting (Estimated)
May 3, 2016
Boston Scientific Corp Annual Shareholders Meeting
More events from DailyFinance »    

Key stats and ratios

Q1 (Mar '16) 2015
Net profit margin 10.29% -3.20%
Operating margin 14.92% -4.37%
EBITD margin - 24.29%
Return on average assets 4.52% -1.36%
Return on average equity 12.68% -3.74%
Employees 25,000 -
CDP Score - 58 E

Address

300 BOSTON SCIENTIFIC WAY
MARLBOROUGH, MA 01752-1234
United States - Map
+1-508-6834000 (Phone)
+1-508-6508923 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money
About Company - Wikipedia

Description

Boston Scientific Corporation is a developer, manufacturer and marketer of medical devices that are used in a range of interventional medical specialties. The Company offers its products by seven core businesses: Interventional Cardiology, Peripheral Interventions (PI), Cardiac Rhythm Management (CRM), Electrophysiology (EP), Endoscopy, Urology and Pelvic Health, and Neuromodulation. It operates in three segments: Cardiovascular, Rhythm Management and MedSurg. Its Cardiovascular segment consists of Interventional Cardiology and PI businesses. Its Rhythm Management segment consists of CRM and EP businesses. Its MedSurg segment consists of Endoscopy, Urology and Pelvic Health, and Neuromodulation businesses. Its interventional cardiology products include Drug-Eluting Coronary Stent Systems, Core Coronary Technology, Intravascular Imaging and Structural Heart Therapy. Its peripheral products include stents, balloon catheters, wires, peripheral embolization devices and vena cava filters.

Officers and directors

Michael F. Mahoney Chairman of the Board, President, Chief Executive Officer
Age: 51
Bio & Compensation  - Reuters
Joseph M. Fitzgerald Executive Vice President and President - Rhythm Management
Age: 52
Bio & Compensation  - Reuters
Daniel J. Brennan Chief Financial Officer, Executive Vice President
Age: 50
Bio & Compensation  - Reuters
Timothy A. Pratt Chief Administrative Officer, Executive Vice President, General Counsel, Secretary
Age: 66
Bio & Compensation  - Reuters
Supratim Bose Executive Vice President and President - Asia-Pacific, Middle East and Africa
Age: 63
Bio & Compensation  - Reuters
Keith D. Dawkins M.D. Global Chief Medical Officer, Executive Vice President
Age: 65
Bio & Compensation  - Reuters
Edward F. Mackey Executive Vice President - Operations
Age: 53
Bio & Compensation  - Reuters
Michael P. Phalen Executive Vice President and President - MedSurg
Age: 56
Bio & Compensation  - Reuters
Wendy Carruthers Senior Vice President - Human Resources
Age: 47
Bio & Compensation  - Reuters
Kevin J. Ballinger Senior Vice President and President - Interventional Cardiology
Age: 43
Bio & Compensation  - Reuters